$HBIO
HARVARD BIOSCIENCE INC Stock $hbio

$hbio Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000117184321003314 Filed on May 07, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$26.99M	$23.77M
YoY Change	13.54%	-15.71%
Cost Of Revenue	$11.56M	$10.79M
YoY Change	7.13%	-10.45%
Gross Profit	$15.43M	$12.98M
YoY Change	18.86%	-19.64%
Gross Profit Margin	57.18%	54.61%
Selling, General & Admin	$11.72M	$12.34M
YoY Change	-5.02%	1.89%
% of Gross Profit	75.94%	95.04%
Research & Development	$2.487M	$2.490M
YoY Change	-0.12%	-8.96%
% of Gross Profit	16.12%	19.18%
Depreciation & Amortization	$445.0K	$484.0K
YoY Change	-8.06%	-10.04%
% of Gross Profit	2.88%	3.73%
Operating Expenses	$15.67M	$16.26M
YoY Change	-3.6%	-0.12%
Operating Profit	-$239.0K	-$3.273M
YoY Change	-92.7%	2627.5%
Interest Expense	-$411.0K	-$1.299M
YoY Change	-68.36%	-7.54%
% of Operating Profit
Other Income/Expense, Net	-$445.0K	-$1.188M
YoY Change	-62.54%	-29.03%
Pretax Income	-$684.0K	-$4.461M
YoY Change	-84.67%	148.66%
Income Tax	-$15.00K	$55.00K
% Of Pretax Income
Net Earnings	-$669.0K	-$4.516M
YoY Change	-85.19%	90.55%
Net Earnings / Revenue	-2.48%	-19.0%
Basic Earnings Per Share	-$0.02	-$0.12
Diluted Earnings Per Share	-$16.84K	-$0.12
COMMON SHARES
Basic Shares Outstanding	39.79M	38.33M
Diluted Shares Outstanding	39.79M	38.33M

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.800M	$5.900M
YoY Change	-1.69%	18.0%
Cash & Equivalents	$5.815M	$5.882M
Short-Term Investments
Other Short-Term Assets	$3.658M	$3.715M
YoY Change	-1.53%
Inventory	$22.68M	$23.14M
Prepaid Expenses
Receivables	$17.07M	$15.43M
Other Receivables	$3.600M	$3.700M
Total Short-Term Assets	$49.22M	$48.17M
YoY Change	2.2%	-10.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.699M	$4.488M
YoY Change	-17.58%	-69.47%
Goodwill	$58.22M	$56.79M
YoY Change	2.51%	-1.02%
Intangibles	$31.89M	$36.81M
YoY Change	-13.36%
Long-Term Investments
YoY Change
Other Assets	$812.0K	$1.881M
YoY Change	-56.83%	25.4%
Total Long-Term Assets	$102.0M	$108.1M
YoY Change	-5.61%	-8.16%
TOTAL ASSETS
Total Short-Term Assets	$49.22M	$48.17M
Total Long-Term Assets	$102.0M	$108.1M
Total Assets	$151.2M	$156.3M
YoY Change	-3.21%	-8.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.416M	$6.625M
YoY Change	-3.15%	-9.38%
Accrued Expenses	$5.400M	$7.449M
YoY Change	-27.51%	-3.26%
Deferred Revenue	$3.637M	$3.673M
YoY Change	-0.98%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.250M	$3.200M
YoY Change	-29.69%	45.45%
Total Short-Term Liabilities	$20.72M	$23.48M
YoY Change	-11.74%	-2.59%
LONG-TERM LIABILITIES
Long-Term Debt	$41.60M	$46.28M
YoY Change	-10.11%	-14.45%
Other Long-Term Liabilities	$2.848M	$862.0K
YoY Change	230.39%	-91.71%
Total Long-Term Liabilities	$44.45M	$47.14M
YoY Change	-5.71%	-26.91%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.72M	$23.48M
Total Long-Term Liabilities	$44.45M	$47.14M
Total Liabilities	$74.13M	$80.25M
YoY Change	-7.62%	-11.81%
SHAREHOLDERS EQUITY
Retained Earnings	-$133.1M	-$129.1M
YoY Change	3.07%
Common Stock	$235.2M	$230.2M
YoY Change	2.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares	$7.746M	$7.746M
Shareholders Equity	$77.12M	$76.01M
YoY Change
Total Liabilities & Shareholders Equity	$151.2M	$156.3M
YoY Change	-3.21%	-8.78%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$669.0K	-$4.516M
YoY Change	-85.19%	90.55%
Depreciation, Depletion And Amortization	$445.0K	$484.0K
YoY Change	-8.06%	-10.04%
Cash From Operating Activities	$1.037M	$2.871M
YoY Change	-63.88%	42.84%
INVESTING ACTIVITIES
Capital Expenditures	$151.0K	$241.0K
YoY Change	-37.34%	68.53%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$301.0K	-$241.0K
YoY Change	24.9%	58.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$500.0K	$4.829M
YoY Change	-89.65%	5.37%
Cash From Financing Activities	-$3.141M	-$5.071M
YoY Change	-38.06%	1.34%
NET CHANGE
Cash From Operating Activities	$1.037M	$2.871M
Cash From Investing Activities	-$301.0K	-$241.0K
Cash From Financing Activities	-$3.141M	-$5.071M
Net Change In Cash	-$2.502M	-$2.453M
YoY Change	2.0%	-21.95%
FREE CASH FLOW
Cash From Operating Activities	$1.037M	$2.871M
Capital Expenditures	$151.0K	$241.0K
Free Cash Flow	$886.0K	$2.630M
YoY Change	-66.31%	40.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39956714
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q1	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0.01
CY2020Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0.01
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47695539
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47152587
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39950032
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39407080
CY2021Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	7745507
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	7745507
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5815000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8317000	USD
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17074000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17766000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	22676000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	22262000	USD
CY2021Q1	us-gaap	Other Assets Current OtherAssetsCurrent	3658000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3355000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	49223000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	51700000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3699000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3960000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7408000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7761000	USD
CY2021Q1	us-gaap	Goodwill Goodwill	58219000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	58590000	USD
CY2021Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	31888000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	33151000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	812000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1092000	USD
CY2021Q1	us-gaap	Assets Assets	151249000	USD
CY2020Q4	us-gaap	Assets Assets	156254000	USD
CY2021Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	1970000	USD
CY2020Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	1721000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2060000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2111000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6416000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5972000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3637000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3771000	USD
CY2021Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6635000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	7478000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	20718000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21053000	USD
CY2021Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	41600000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	46286000	USD
CY2021Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1809000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1899000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7159000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7481000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2848000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2854000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	74134000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	79573000	USD
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	448000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	444000	USD
CY2021Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	234781000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	232357000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-133055000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-132386000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-14391000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-13066000	USD
CY2021Q1	us-gaap	Treasury Stock Carrying Basis TreasuryStockCarryingBasis	10668000	USD
CY2020Q4	us-gaap	Treasury Stock Carrying Basis TreasuryStockCarryingBasis	10668000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	77115000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	76681000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	151249000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	156254000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26989000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23771000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	11558000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10789000	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	15431000	USD
CY2020Q1	us-gaap	Gross Profit GrossProfit	12982000	USD
CY2021Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5386000	USD
CY2020Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5579000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6333000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6759000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2487000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2490000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1464000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1427000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	15670000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	16255000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-239000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3273000	USD
CY2021Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-411000	USD
CY2020Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1299000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-34000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	111000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-445000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1188000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-684000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-4461000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-15000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	55000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-669000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-4516000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39787000
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38329000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-669000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-4516000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1325000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1576000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	0	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	-216000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	-0	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	-72000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	0	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-144000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1325000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1720000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1994000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6236000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	76681000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1924000	USD
CY2021Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	464000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	968000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-669000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1325000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	77115000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	81694000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2020Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	242000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	793000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-4516000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1720000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	76009000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-669000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-4516000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	445000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	484000	USD
CY2021Q1	hbio	Amortization Of Intangible Assets Including Amounts Related To Discontinued Operation AmortizationOfIntangibleAssetsIncludingAmountsRelatedToDiscontinuedOperation	1464000	USD
CY2020Q1	hbio	Amortization Of Intangible Assets Including Amounts Related To Discontinued Operation AmortizationOfIntangibleAssetsIncludingAmountsRelatedToDiscontinuedOperation	1427000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	70000	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	98000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	968000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	793000	USD
CY2021Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	53000	USD
CY2020Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	162000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-584000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5149000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	602000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1413000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	94000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	767000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-245000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2739000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-135000	USD
CY2020Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-256000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-696000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-705000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1037000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2871000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	151000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	241000	USD
CY2021Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	150000	USD
CY2020Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	-0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-301000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-241000	USD
CY2021Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	4500000	USD
CY2020Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	4829000	USD
CY2021Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	101000	USD
CY2020Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	-0	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1924000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2021Q1	hbio	Net Taxes Paid Net Proceeds From Issuance Of Common Stock NetTaxesPaidNetProceedsFromIssuanceOfCommonStock	-464000	USD
CY2020Q1	hbio	Net Taxes Paid Net Proceeds From Issuance Of Common Stock NetTaxesPaidNetProceedsFromIssuanceOfCommonStock	-242000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3141000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5071000	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-97000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-12000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2502000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2453000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8317000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8335000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5815000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5882000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	458000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	1237000	USD
CY2021Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-113000	USD
CY2020Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	110000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	4373000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	5798000	USD
CY2021Q1	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"> <tbody> <tr> <td style="vertical-align:top;width:2.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">2.</em></b></p> </td> <td style="vertical-align:top;width:43.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Recently Issued Accounting Pronouncements</b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:18pt;"><i>Accounting Pronouncements Adopted</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">In <em style="font: inherit;"> December 2019, </em>the FASB issued ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12,</em> Income Taxes (Topic <em style="font: inherit;">740</em>): Simplifying the Accounting for Income Taxes (ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em>), which enhances and simplifies various aspects of the income tax accounting guidance related to intra-period tax allocation, interim period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim period tax accounting. ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> also amends other aspects of the guidance to reduce complexity in certain areas. The Company adopted the provisions of ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> effective on <em style="font: inherit;"> January 1, 2021. </em>The adoption of this new accounting guidance did <em style="font: inherit;">not</em> have a material impact on the Company’s consolidated financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:18pt;"><i>Accounting Pronouncements to be Adopted</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">In <em style="font: inherit;"> September 2016, </em>the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments</i>—<i>Credit Losses (Topic <em style="font: inherit;">326</em>): Measurement of Credit Losses on Financial</i> <i>Instruments (ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em>), </i>which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather than incurred<i> </i>losses to estimate credit losses on certain types of financial instruments, including trade receivables. This <em style="font: inherit;"> may </em>result in the earlier recognition of allowances for losses. The FASB issued several ASUs after ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> to clarify implementation guidance and to provide transition relief for certain entities. ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> is effective for the Company for fiscal years beginning after <em style="font: inherit;"> December 15, 2022, </em>with early adoption permitted. The Company is evaluating the impact that adopting ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> and related amendments will have on its consolidated financial position, results of operations and cash flows.</p>
CY2020Q4	us-gaap	Goodwill Goodwill	58590000	USD
CY2021Q1	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-371000	USD
CY2021Q1	us-gaap	Goodwill Goodwill	58219000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	65431000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	33788000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	31643000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	65679000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	32782000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	32897000	USD
CY2021Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	245000	USD
CY2020Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	254000	USD
CY2021Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	31888000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	33151000	USD
CY2021Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1500000	USD
CY2020Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1400000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	5690000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	5385000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	4273000	USD
CY2021Q1	hbio	Finitelived Intangible Asset Expected Amortization After Year Four FinitelivedIntangibleAssetExpectedAmortizationAfterYearFour	6124000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	31643000	USD
CY2021Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5114000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4938000	USD
CY2021Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3544000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3513000	USD
CY2021Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	14018000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	13811000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	22676000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	22262000	USD
CY2021Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2711000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3715000	USD
CY2021Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	432000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	432000	USD
CY2021Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	168000	USD
CY2020Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	185000	USD
CY2021Q1	hbio	Customer Related Costs CustomerRelatedCosts	1010000	USD
CY2020Q4	hbio	Customer Related Costs CustomerRelatedCosts	1093000	USD
CY2021Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	206000	USD
CY2020Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	286000	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2108000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1767000	USD
CY2021Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6635000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	7478000	USD
CY2020Q4	us-gaap	Restructuring Reserve RestructuringReserve	288000	USD
CY2021Q1	us-gaap	Restructuring Charges RestructuringCharges	553000	USD
CY2021Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	274000	USD
CY2021Q1	us-gaap	Restructuring Reserve RestructuringReserve	567000	USD
CY2021Q1	us-gaap	Restructuring Charges RestructuringCharges	600000	USD
CY2020Q1	us-gaap	Restructuring Charges RestructuringCharges	900000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	517000	USD
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	535000	USD
CY2021Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	46000	USD
CY2020Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	42000	USD
CY2021Q1	us-gaap	Sublease Income SubleaseIncome	25000	USD
CY2020Q1	us-gaap	Sublease Income SubleaseIncome	107000	USD
CY2021Q1	us-gaap	Lease Cost LeaseCost	538000	USD
CY2020Q1	us-gaap	Lease Cost LeaseCost	470000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	611000	USD
CY2020Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	687000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7408000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7761000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2060000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2111000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7159000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7481000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	9219000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	9592000	USD
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y3M18D
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.61
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y4M24D
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.093	pure
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.093	pure
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2060000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1981000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1953000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1482000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	981000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	4611000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	13068000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3849000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	9219000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2637339
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.51
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2021Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	310169
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.01
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	474309
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	4.64
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1852861
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.14
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	968000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	793000	USD
CY2021Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	7800000	USD
CY2021Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y4M24D
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39787281
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38328791
CY2021Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2020Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39787281
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38328791
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4883260
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4222425
CY2021Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1330000	USD
CY2020Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1393000	USD
CY2021Q1	us-gaap	Long Term Debt LongTermDebt	43570000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	48007000	USD
CY2021Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	2250000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2000000	USD
CY2021Q1	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	280000	USD
CY2020Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	279000	USD
CY2021Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	41600000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	46286000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	-216000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	-72000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-144000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26989000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23771000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26989000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23771000	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3771000	USD
CY2021Q1	hbio	Contract With Customer Liability Deferred Revenue ContractWithCustomerLiabilityDeferredRevenue	1592000	USD
CY2021Q1	hbio	Contract With Customer Liability Recognition Of Deferred Revenue ContractWithCustomerLiabilityRecognitionOfDeferredRevenue	1723000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	-3000	USD
CY2021Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3637000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3949000	USD
CY2020Q1	hbio	Contract With Customer Liability Deferred Revenue ContractWithCustomerLiabilityDeferredRevenue	531000	USD
CY2020Q1	hbio	Contract With Customer Liability Recognition Of Deferred Revenue ContractWithCustomerLiabilityRecognitionOfDeferredRevenue	821000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	14000	USD
CY2020Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3673000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	227000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	325000	USD
CY2021Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	5000	USD
CY2020Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	4000	USD
CY2021Q1	hbio	Accounts Receivable Allowance For Credit Loss Chargeoffs And Other Reoveries AccountsReceivableAllowanceForCreditLossChargeoffsAndOtherReoveries	-26000	USD
CY2020Q1	hbio	Accounts Receivable Allowance For Credit Loss Chargeoffs And Other Reoveries AccountsReceivableAllowanceForCreditLossChargeoffsAndOtherReoveries	31000	USD
CY2021Q1	hbio	Accounts Receivable Allowance For Credit Loss Effect Of Foreign Currency Translation AccountsReceivableAllowanceForCreditLossEffectOfForeignCurrencyTranslation	-4000	USD
CY2020Q1	hbio	Accounts Receivable Allowance For Credit Loss Effect Of Foreign Currency Translation AccountsReceivableAllowanceForCreditLossEffectOfForeignCurrencyTranslation	-1000	USD
CY2021Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	254000	USD
CY2020Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	297000	USD
CY2021Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.022	pure
CY2020Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.012	pure

Files In Submission

Name	View Source	Status
0001171843-21-003314-index-headers.html	Edgar Link	pending
0001171843-21-003314-index.html	Edgar Link	pending
0001171843-21-003314.txt	Edgar Link	pending
0001171843-21-003314-xbrl.zip	Edgar Link	pending
ex_246340.htm	Edgar Link	pending
ex_246341.htm	Edgar Link	pending
ex_246342.htm	Edgar Link	pending
ex_246343.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
hbio-20210331.xsd	Edgar Link	pending
hbio-20210331_cal.xml	Edgar Link	unprocessable
hbio-20210331_def.xml	Edgar Link	unprocessable
hbio-20210331_lab.xml	Edgar Link	unprocessable
hbio-20210331_pre.xml	Edgar Link	unprocessable
hboi20210331_10q.htm	Edgar Link	pending
hboi20210331_10q_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HBIO
HARVARD BIOSCIENCE INC Stock $hbio

2021 Q1 Form 10-Q Financial Statement

#000117184321003314 Filed on May 07, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HBIO HARVARD BIOSCIENCE INC Stock $hbio

2021 Q1 Form 10-Q Financial Statement

#000117184321003314 Filed on May 07, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HBIO
HARVARD BIOSCIENCE INC Stock $hbio